Ultragenyx Pharmaceutical shares plunged 47.6% to $13.89 in Thursday morning trading after its apazunersen treatment missed main and secondary goals in a late-stage Angelman syndrome trial. The failure wiped out $1.25 billion in market value. It marks the company's second consecutive late-stage trial failure, eroding investor confidence in a key growth pipeline.

Pipeline Setback Triggers Cutbacks